[1] Tsochatzis EA,Bosch J,Burroughs AK. Liver cirrhosis. Lancet,2014,383:1749-1761.
[2] Sanyal AJ,Bosch J,Blei A,et al. Portal hypertension and its complications. Gastroenterology,2008,134:1715-1728.
[3] Garcia-Tsao G,Sanyal AJ,Grace ND,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology,2007,46:922-938.
[4] Giannelli V,Lattanzi B,Thalheimer U,et al. Beta-blockers in liver cirrhosis.Ann Gastroenterol,2014,27:20-26.
[5] Tripathi D,Hayes PC. Beta-blockers in portal hypertension:new developments and controversies. Liver Int,2014,34:655-667.
[6] 莫翠毅,李世立.卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度的近期疗效比较.世界华人消化杂志,2014,22: 4146-4150.
[7] 李晶,孙东杰,王广川,等.卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度效果的对比分析.临床肝胆病杂志,2016,32: 114-118.
[8] 任荣荣. 卡维地洛与普萘洛尔降低肝硬化门静脉高压患者HVPG的近期疗效比较. 济南:山东大学,2012.
[9] 王雪颖.不同肝静脉压力梯度(HVPG)对非选择性β受体阻滞剂应答率的影响. 济南:山东大学,2013.
[10] 孙东杰.普萘洛尔和卡维地洛降低肝静脉压力梯度疗效及影响因素分析. 济南:山东大学,2015.
[11] Kim SG,Kim TY,Sohn JH,et al. A Randomized,Multi-Center,Open-Label Study to Evaluate the Efficacy of Carvedilol vs.Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol,2016,111:1582-1590.
[12] Gupta V,Rawat R,Shalimar,et al. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed:RCT.Hepatol Int,2016, 11: 181-187.
[13] Reiberger T,Ulbrich G,Ferlitsch A,et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut,2013,62:1634-1641.
[14] Hobolth L, Bendtsen F, Hansen EF,et al. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis:a randomised study. Dig Liver Dis,2014, 46: 251-256.
[15] De BK,Das D,Sen S,et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatology, 2002, 17: 183-189.
[16] Banares R, Moitinto E, Piqueras B,et al. Carvedilol,a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity,has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology,1999, 30: 79-83.
[17] Hobolth L, Møller S,Grønbæk,et al. Carvedilol or propranolol in portal hypertension？A randomized comparison. Scand J Gastroenterol,2012, 47: 467-474.
[18] Banares R,Moitinho E,Matilla A,et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology,2002, 36: 1367-1373.
[19] 李波,黄志刚,沈健伟,等. 卡维地洛与普萘洛尔降低肝硬化门静脉高压效果的对照研究. 浙江医学,2012,34:1973-1975.
[20] 郑晓宇. 肝脏储备功能对非选择性β-受体阻断剂(NSBB)降低肝静脉压力梯度(HVPG)疗效的影响. 济南:山东大学,2014.
[21] 曲春晓. 肝静脉压力梯度短期变化预测β受体阻滞剂长期疗效的初步研究. 济南:山东大学,2012.
[22] D'Amico G,Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol,1997,11:243-256.
[23] Norberto L,Polese L,Cillo U,et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl,2007,13:1272-1278. |
